As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

Synthetic Oligonucleotides are set for rapid expansion in healthcare, food production, and data storage. The technology, vital in both existing and new markets, promises vast growth potential often ...

The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...

New York, USA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | ...

This study addresses endosomal escape in oligonucleotide therapies and how engineered peptides can enhance intracellular drug delivery efficiency.

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market: Forecast by Oligo Length, Application, Category, Type, Product, and Region, with Executive and Consultant Guides" report has been added ...

Oligonucleotide therapeutics, which can modulate gene expression by a variety of mechanisms, have the potential to treat numerous diseases. Although several oligonucleotide-based drugs have recently ...

Oligonucleotide therapeutics make up a small but rapidly growing segment of the overall global drug pipeline, with 245 programs currently in development today. While only one approved oligo ...

GSK has added another oligonucleotide to its pipeline, with potentially plenty more to follow courtesy of a $170 million upfront collaboration with Wave Life Sciences. As part of the deal, GSK will ...

Antisense oligonucleotide (ASO) therapy has the potential to ameliorate many neurodegenerative diseases at the genetic level to suppress the production of harmful proteins or non-coding RNAs.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent ...